Having Achieved Quality, Downstream Teams Seek To Maximize Viral Vector Recovery

Why It Matters

Optimizing downstream recovery now improves regulatory compliance and prepares companies for scalable, cost‑effective manufacturing as gene‑therapy markets expand.

Key Takeaways

• Vector recovery rates remain low, prompting focus on optimization.
• Purity and CQA targets are regulatory priorities, not cost.
• Scalability and commercial readiness are low current priorities.
• Early process changes reduce regulatory burden in later trials.
• DOE runs per unit operation can boost recovery to 45‑48%.

Summary

The panel discussed how downstream teams, having secured vector quality, are now concentrating on maximizing viral vector recovery. Participants highlighted that recovery yields remain modest, prompting a shift from pure cost concerns to meeting purity and CQA specifications required by regulators.

Data showed industry‑average lentiviral recovery hovers around 30%, but careful optimization can lift yields to 45‑48%. Attendees emphasized that purity targets and CQA compliance dominate decision‑making, while cost reduction and scalability rank far lower on current priorities.

A speaker cited a multi‑step chromatography workflow—size‑exclusion followed by ion‑exchange—to separate exosomes (30‑300 nm) from viral particles (<120 nm). By rapidly neutralizing the eluate and fine‑tuning each unit operation via design‑of‑experiments (DOE), they achieved the higher recovery rates.

The discussion underscores that early process adjustments and rigorous DOE studies can mitigate later regulatory hurdles and position biotechs for smoother scale‑up, even as cost and commercial readiness become more pressing in future phases.

Original Description

In this segment from the Bioprocess Online Live event, "Downstream Decisions To Maximize Viral Vector Yields And Reduce COGs," our panelists react to an audience poll about which factors most drive their downstream decisions.